Lurasidone and Risk for Metabolic Syndrome: Results from Short and Long-term Clinical Studies in Patients with Schizophrenia.

Lurasidone and Risk for Metabolic Syndrome: Results from Short and Long-term Clinical Studies in Patients with Schizophrenia. CNS Spectr. 2020 Sep 14;:1-26 Authors: Tocco M, Newcomer JW, Mao Y, Pikalov A, Loebel A PMID: 32921337 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32921337?dopt=Abstract

Source: CNS Spectrums - September 13, 2020 Category: Neurology Authors: Tocco M, Newcomer JW, Mao Y, Pikalov A, Loebel A Tags: CNS Spectr Source Type: research

More News: Metabolic Syndrome | Neurology | Schizophrenia | Study